Clinical Trial Update: M6620 (VX-970) in Selected Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of M6620 (VX-970) in selected solid tumors completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Osteosarcoma
• Solid Tumor

Drugs mentioned

• M6620 (berzosertib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Solid Tumor, Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-07